Abstract
Many patients with colorectal liver metastasis cannot be cured of their disease. This is because it has spread widely throughout the liver and is therefore not resectable. In this context, palliative chemotherapy is the main treatment modality. Moreover, in many of these patients, the primary tumor that caused the problem is relatively asymptomatic, and from a clinical perspective, a major problem in dealing with these patients is what to do with the primary cancer. In other words, it is a matter of great debate whether some of these patients benefit from a palliative primary tumor resection once some studies have suggested that resecting the primary cancer can prolong survival and prevent complication arising from the cancer, such as obstruction or bleeding. This review addresses the question of whether surgically removing the primary cancer is beneficial to patients with unresectable colorectal liver metastasis.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.
Feo L, Polcino M, Nash G. Resection of the primary tumor in stage IV colorectal cancer: when is it necessary? Surg Clin North Am. 2017;97:657–69.
Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of Surveillance, Epidemiology, and End Results data, 1988 to 2000. Ann Surg Oncol. 2005;12:637–45.
Verhoef C, Wilt J, Burger J, et al. Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer. 2011 Sep;47(Suppl 3):S61–6.
Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–71.
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.
Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19(11):1829–35. https://doi.org/10.1093/annonc/mdn398. Epub 2008 Jul 28; Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379−84.
Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52(4):568–73.
Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6(7):651–7.
Mahteme H, Pahlman L, Glimelius B, Graf W. Prognosis after surgery in patients with incurable rectal cancer: a population based study. Br J Surg. 1996;83(8):1116–20.
Crane CH, Janjan NA, Abbruzzese JL, et al. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys. 2001;49(1):107–16.
Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum. 1990;33(10):846–50.
Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer − is it worthwhile? Dis Colon Rectum. 1997;40(1):11–4.
Konyalian VR, Rosing DK, Haukoos JS, et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Color Dis. 2007;9(5):430–7.
Beham A, Rentsch M, Pullmann K, et al. Survival benefit in patients after palliative resection vs non-resection colon cancer surgery. World J Gastroenterol. 2006;12(41):6634–8.
Costi R, Mazzeo A, Di Mauro D, et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol. 2007;14(9):2567–76.
Law WL, Chan WF, Lee YM, Chu KW. Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Color Dis. 2004;19(3):197–202.
Mik M, Dziki L, Galbfach P, et al. Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients? Color Dis. 2010;12(7 Online):e61–7.
Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89(4):211–7.
Yun HR, Lee WY, Lee WS, et al. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient’s status. Int J Color Dis. 2007;22(11):1301–10.
Frago R, Kreisler E, Biondo S, et al. Outcomes in the management of obstructive unresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010;36(12):1187–94.
Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg. 2010;8(4):305–13.
Ruo L, Gougoutas C, Paty PB, et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196(5):722–8.
Kaufman MS, Radhakrishnan N, Roy R, et al. Influence of palliative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institutional study. Color Dis. 2008;10(5):498–502.
Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with nonresectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28(5):434–7.
Benoist S, Pautrat K, Mitry E, et al. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92(9):1155–60.
Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352–8; discussion: 358.
Bajwa A, Blunt N, Vyas S, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol. 2009;35(2):164–7.
Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. Am J Clin Oncol. 2010;33(1):52–5.
Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol. 2009;7:28.
Seo GJ, Park JW, Yoo SB, et al. Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol. 2010;102(1):94–9.
Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370(9582):135–42.
Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563–72.
Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011 Nov;18(12):3252–60.
Koopman M, Antonini NF, Douma J, et al. Sequential versus combination therapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized controlled trial. Lancet. 2007;370:135–42.
Tol J, Koopman M, Rodenburg CJ, et al. A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer: the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008;19:734–8.
Ahmed S, Leis A, Chandra-Kanthan S, et al. Surgical management of the primary tumor in stage IV colorectal cancer: a confirmatory retrospective cohort study. J Cancer. 2016;7:837–45.
Faron M, Pignon JP, Malka D, et al. Is primary tumor resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomized trials. Eur J Cancer. 2015;51:166–76.
Ducreux M, Bouche O, Pignon JP, et al. Randomized trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 trial. Oncology. 2006;70:222–30.
Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomized, phase 3 trial. Lancet Oncol. 2011;12:1032–44.
Ducreux M, Adenis A, Mendiboure J, et al. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV1FOLFIRI versus BEV1XELIRI (FNCLCC ACCORD-13/0503). Abstr Annu Meet Am Soc Clin Oncol. 2009;27:4086.
Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011;128:682–90.
Clancy C, Burke JP, Barry M, et al. A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. 2014;21:3900–8.
Tarantino I, Warschkow R, Worni M, et al. Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients. A population-based, propensity score-adjusted trend analysis. Ann Surg. 2015;262:112–20.
Lam-Boer J, Van der Geest L, Verhoef C, et al. Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: a nationwide population-based propensity-score adjusted study in the Netherlands. Int J Cancer. 2016;139:2082–94.
He WZ, Rong YM, Jiang C, et al. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen. Chin J Cancer. 2016;35(1):58–65.
Kodaz H, Erdogan B, Hacibekiroglu I, et al. Primary tumor resection offers higher survival advantage in KRAS mutant metastatic colorectal cancer patients. Hepatogastroenterology. 2015;62(140):876–9.
Dorajoo SR, Tan WJ, Koo SX, et al. A scoring model for predicting survival following primary tumour resection in stage IV colorectal patients with unresectable metastasis. Int J Color Dis. 2016;31(2):235–45.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Valadão, M., Gonçalves, R., Araújo, R., de Almeida Gil, R. (2020). Resection of the Primary in Unresectable Colorectal Cancer Liver Metastases – Is It Worth?. In: Correia, M., Choti, M., Rocha, F., Wakabayashi, G. (eds) Colorectal Cancer Liver Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-25486-5_33
Download citation
DOI: https://doi.org/10.1007/978-3-030-25486-5_33
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-25485-8
Online ISBN: 978-3-030-25486-5
eBook Packages: MedicineMedicine (R0)